Eiger BioPharmaceuticals to Host Conference Call for Third Quarter 2022 Financial Results and Business Update on Thursday, November 3

Rhea-AI Summary

Eiger BioPharmaceuticals (Nasdaq: EIGR) announced a conference call on November 3, 2022, at 4:30 PM ET to discuss its third quarter 2022 financial results and provide a business update. The company is focused on developing innovative therapies for hepatitis delta virus (HDV) and other serious diseases, with two first-in-class therapies in Phase 3 that target viral replication. All five rare disease programs have received FDA breakthrough therapy designation.

Positive

• Eiger's HDV platform includes two first-in-class therapies in Phase 3.
• All five rare disease programs have received FDA breakthrough therapy designation.

Negative

• None.

-  Live Conference Call and Webcast at 4:30 PM ET  -

PALO ALTO, Calif., Oct. 24, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, November 3, 2022 at 4:30 PM ET to discuss its third quarter 2022 financial results and provide a business update.

The live and replayed webcast of the call will be available through the company's website at www.eigerbio.com. To participate in the live call by phone, please register in advance at https://register.vevent.com/register/BI87b8efa326b64c63bd59eabef4f465ab to receive the dial-in number and unique passcode to access the call. The webcast will be archived and available for replay for at least 90 days after the event.

About Eiger

Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. All five Eiger rare disease programs have been granted FDA breakthrough therapy designation.

For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com 

Media:
Sarah Mathieson
SVP, Corporate Affairs
smathieson@eigerbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-host-conference-call-for-third-quarter-2022-financial-results-and-business-update-on-thursday-november-3-301657595.html

SOURCE Eiger BioPharmaceuticals, Inc.

FAQ

When is Eiger BioPharmaceuticals' third quarter 2022 earnings call?

Eiger BioPharmaceuticals will host its third quarter 2022 earnings call on November 3, 2022, at 4:30 PM ET.

What is the focus of Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals focuses on developing therapies for hepatitis delta virus (HDV) and other serious rare diseases.

What advancements has Eiger made in its HDV platform?

Eiger's HDV platform includes two first-in-class therapies currently in Phase 3 trials.

What does FDA breakthrough therapy designation mean for Eiger's programs?

FDA breakthrough therapy designation means Eiger's rare disease programs have been recognized for their potential to provide significant improvements over existing treatments.